Mineralys (NASDAQ: MLYS) CCO sells 7,438 shares after option exercise
Rhea-AI Filing Summary
Mineralys Therapeutics Chief Commercial Officer Eric Warren exercised 7,438 stock options for common shares at $13.24 per share and, on the same date, sold 7,438 shares at a weighted-average price of $26.8735 (within a $26.53–$27.09 range) under a Rule 10b5-1 plan adopted March 27, 2026. After the exercise, he continues to hold 245,438 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,438 shares ($101K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Warren Eric
Role
Chief Commercial Officer
Sold
7,438 shs ($200K)
Approx. gross sale proceeds
$200K
Approx. exercise cost
$98K
Approx. pre-tax spread
$101K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F3 | 7,438 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 7,438 | $13.24 | $98K |
| Sale | Common Stock F1, F2 | 7,438 | $26.8735 | $200K |
Holdings After Transaction:
Stock Option — 245,438 shares (Direct);
Common Stock — 38,400 shares (Direct)
Footnotes (3)
- F1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
- F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.53 to $27.09. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- F3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Key Figures
Options exercised: 7,438 shares
Exercise price: $13.24 per share
Shares sold: 7,438 shares
+3 more
6 metrics
Options exercised
7,438 shares
Stock options converted to common stock on July 21, 2026
Exercise price
$13.24 per share
Conversion or exercise price for the stock options exercised
Shares sold
7,438 shares
Common stock sold on July 21, 2026 following the option exercise
Sale price
$26.8735 per share
Weighted-average sale price; individual trades between $26.53 and $27.09
Remaining options
245,438 shares
Stock options held directly after the reported exercise
10b5-1 plan adoption
March 27, 2026
Date the Rule 10b5-1 stock selling plan governing these trades was adopted
Key Terms
Rule 10b5-1, weighted-average price, stock option
3 terms
Rule 10b5-1 regulatory
"These transactions were effected pursuant to a Rule 10b5-1 stock selling plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted-average price financial
"The price reported in Column 4 is a weighted-average price"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
stock option financial
"The stock option vested as to 25% of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Mineralys Therapeutics (MLYS) report for Eric Warren?
Mineralys Therapeutics reported that CCO Eric Warren exercised 7,438 stock options at $13.24 per share, received 7,438 common shares, and sold 7,438 shares at a weighted-average price of $26.8735 on July 21, 2026, in a linked option exercise-and-sale sequence.
What option exercise did Mineralys (MLYS) disclose for its Chief Commercial Officer?
The company disclosed that Eric Warren exercised 7,438 stock options, converting them into the same number of common shares at an exercise price of $13.24 per share. The stock option grant vested 25% after one year, with the balance vesting in 36 monthly installments.
Was the Mineralys (MLYS) insider trade done under a Rule 10b5-1 plan?
Yes. Footnotes state these transactions were effected under a Rule 10b5-1 stock selling plan adopted on March 27, 2026. The plan designation and the filing’s 10b5-1 checkbox indicate the trades followed a pre-arranged trading program.
How many Mineralys (MLYS) stock options does Eric Warren hold after the reported transactions?
After exercising 7,438 options, Eric Warren directly holds 245,438 stock options in Mineralys Therapeutics. This figure reflects the remaining derivative position reported following the option exercise transaction, with an expiration date of April 21, 2035, for the exercised grant.